Immunotherapy in malignant peritoneal mesothelioma (Review).

Area of Science:

• Oncology
• Immunotherapy
• Cancer Research

Background:

• Cancer treatment is shifting towards immunotherapy, including immune checkpoint inhibitors (ICIs).
• ICIs are effective in various solid tumors, but patients with malignant peritoneal mesothelioma (MPeM) are often excluded from trials.
• This exclusion hinders progress in MPeM treatment, forcing reliance on limited retrospective data.

Purpose of the Study:

• To review existing clinical data on immunotherapy for MPeM.
• To evaluate the role of the tumor microenvironment and biomarkers in ICI efficacy for MPeM.
• To propose a strategy for using immunotherapy in MPeM treatment.

Main Methods:

• Review of clinical studies investigating immunotherapy in MPeM.
• Analysis of tumor microenvironment factors relevant to ICI therapy.
• Evaluation of validated biomarkers for predicting ICI response.

Main Results:

• Limited clinical data exists for ICIs in MPeM, highlighting a significant knowledge gap.
• The tumor microenvironment and specific biomarkers are crucial for ICI efficacy, but their role in MPeM requires further investigation.
• Current evidence suggests potential but lacks definitive consensus for ICIs in MPeM.

Conclusions:

• There is no established consensus on using ICIs for malignant peritoneal mesothelioma.
• Further research and clinical trials are essential to define the role of immunotherapy in MPeM.
• A strategic approach incorporating tumor microenvironment and biomarker data may optimize immunotherapy use in MPeM.